Role of interferons in the therapy of melanoma.

The increased incidence of disease, the relative unresponsiveness of advanced tumour to conventional therapies, and high socioeconomic costs make the malignant melanoma an aggressive cancer. During the last decade, several new biological agents have been developed, some of which have shown significant activity in the treatment of disease. However, the impact on the management of melanoma patients is still far from being conclusive.

Treatment of advanced colorectal cancer with mitoxantrone, high dose folinic acid and fluorouracil.

A new combination chemotherapy including mitoxantrone 10 mg/m2 i.v. on day 1 and 5-fluorouracil 400 mg/m2 i.

Combination chemotherapy with vinblastine, BCNU and cisplatin in advanced malignant melanoma.

A combination chemotherapy including vinblastine (6 mg/m2 i.v. days 1-2), BCNU (100 mg/m2 i.

Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, and bleomycin.

A combination of cisplatin (60 mg/m2 i.v. on day 1), etoposide (100 mg/m2 i.